TITLE

Under the Weather

AUTHOR(S)
Herper, Matthew; Schoenberger, Chana R.
PUB. DATE
February 2008
SOURCE
Forbes Asia;2/11/2008, Vol. 4 Issue 3, p38
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the growth of Japanese drug firms in the international market. Japanese drugmakers are growing faster outside Japan than in it since Japanese drugs get hit with price cuts every year. But Japan's drugmakers, like their U.S. peers, face looming patent expirations and depressing research failures. Takeda recently stopped testing the most powerful dose of a promising cholesterol drug because it caused liver problems. Eisai is facing a two-year delay on a treatment for Parkinson's disease.
ACCESSION #
31193717

 

Related Articles

  • COMPANY SPOTLIGHT -- Takeda Pharmaceutical Company.  // PharmaWatch: Cancer;Jun2010, Vol. 9 Issue 6, p17 

    A company profile of Takeda Pharmaceutical Co. Ltd., which develops new drugs including agents for diabetes, ulcers, hypertension, osteoroporosis and others, is presented. An overview of the company is given, along with key facts including products, subsidiaries and equity method affiliates. An...

  • TOP 20 PHARMA: #14 TAKEDA.  // Contract Pharma;2009, Vol. 11 Issue 6, p83 

    The article profiles Takeda Pharmaceutical Co. Ltd., the rank 14 among the top 20 pharmaceutical companies based in Osaka, Japan. It states that the company was established in 1781 and holds 19,362 employees. It tells that it has received an approval of its Actos/metformin XR combo, Kapidex and...

  • Takeda Pharmaceutical Company Limited SWOT Analysis.  // Takeda Chemical Industries, Ltd. SWOT Analysis;May2012, p1 

    A company profile of Japan-based Takeda Pharmaceutical Co. Ltd. is presented. An overview of the company is given, along with key facts including contact information, number of employees and revenues. A business analysis is provided which includes strengths, weaknesses, opportunities for...

  • Takeda Pharmaceutical Company Limited SWOT Analysis.  // Takeda Chemical Industries, Ltd. SWOT Analysis;Feb2013, p1 

    A business analysis of Takeda Pharmaceutical Co. Ltd., a pharmaceuticals company located in Osaka, Japan is presented, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company. The increasing market share of the internally-developed drugs has driven the...

  • Takeda Pharmaceutical Company Limited SWOT Analysis.  // Takeda Chemical Industries, Ltd. SWOT Analysis;Mar2014, p1 

    A business analysis of Osaka, Japan-based Takeda Pharmaceutical Co. Ltd. is provided, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company. Strengths include revenue growth derived from its increasing market share of drugs. Weaknesses include withdrawal...

  • DATAMONITOR: Takeda Pharmaceutical Company Limited.  // Takeda Chemical Industries, Ltd. SWOT Analysis;Dec2009, p1 

    A company profile of Takeda Pharmaceutical Co. Ltd., which is the largest pharmaceutical company in Japan engaged in the discovery, development, manufacture and marketing a range of pharmaceutical products, is presented. An overview of the company is given, along with key facts including contact...

  • STRUCTURAL INERTIA, IMITATION, AND FOREIGN EXPANSION: SOUTH KOREAN FIRMS AND BUSINESS GROUPS IN CHINA, 1987-95. Guillen, Mauro F. // Academy of Management Journal;Jun2002, Vol. 45 Issue 3, p509 

    The foreign expansion of firms is treated as an instance of organizational and strategic change shaped by structural inertia and imitation. A longitudinal analysis of South Korean firms in China shows that business group experience and imitation among firms from the same home-country industry...

  • Takeda Acquires LigoCyte Pharma.  // Contract Pharma;Nov/Dec2012, Vol. 14 Issue 9, p94 

    The article offers information related to pharmaceutical industry acquisition. It says that LigoCyte Pharmaceuticals Inc. will be acquired by Takeda Pharmaceutical Co. Ltd. as part of the company's expansion for its vaccine business. It mentions that Pfizer Inc. has entered an option and merger...

  • Vaccine Division in Works at Takeda.  // Chain Drug Review;1/16/2012, Vol. 34 Issue 2, p57 

    The article reports on the plan of diatric vaccine supplier Takeda Pharmaceutical Co. Ltd. in establishing a vaccine business division as part of their effort to strengthen the foundation for expansion for vaccine business of the company.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics